ClinicalTrials.gg

Program

inaxaplin

Also written as “VX-147”, “IXP” and “Inaxaplin”.

Its studies are mostly in Glomerulosclerosis, Focal Segmental · Renal Insufficiency, led by Vertex Pharmaceuticals.

Furthest: phase 3, since Mar 28, 20226 company-led studies, 1 open or runningNext primary completion: Jun 2, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals61 open or runningphase 3since Mar 28, 2022Apr 7, 2020Jun 2, 2028phase 3 · NCT05312879

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2020First study: phase 2 study in Glomerulosclerosis, Focal SegmentalFirst studyNCT04340362 · 16 enrolled · United States, France, Puerto Rico and more
  2. Mar 28, 2022Phase 3 study in Proteinuric Kidney DiseaseNCT05312879 · 522 enrolled · United States, Belgium, Brazil and more
  3. May 9, 2023Phase 1 study in Renal InsufficiencyNCT05865171 · 16 enrolled · United States
  4. Jul 13, 2023Phase 1 study in Glomerulosclerosis, Focal SegmentalNCT05955872 · 21 enrolled · United States
  5. Jul 26, 2024Phase 1 study in Glomerulosclerosis, Focal SegmentalNCT06529796 · 36 enrolled · United States
  6. Jan 23, 2025Phase 2 study in Proteinuric Kidney DiseaseNCT06794996 · 42 enrolled · United States

Ahead

  1. Jun 2, 2028Primary completion: phase 3 study in Proteinuric Kidney DiseaseNCT05312879

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06794996Proteinuric Kidney Disease · United States2CompletedJul 20, 202642
NCT06529796Glomerulosclerosis, Focal Segmental · United States1CompletedDec 20, 202436
NCT05955872Glomerulosclerosis, Focal Segmental · United States1CompletedSep 2, 202321
NCT05865171Renal Insufficiency · United States1CompletedJun 12, 202416
NCT05312879Proteinuric Kidney Disease · United States, Belgium, Brazil and more3Active, not recruitingJun 2, 2028522
NCT04340362Glomerulosclerosis, Focal Segmental · United States, France, Puerto Rico and more2CompletedNov 11, 202116

How it is read

Names in the registry

  • “VX-147”, 3 entries
  • “IXP”, 2 entries
  • “Inaxaplin”, 1 entry

Codes read as this program: VX147.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.